RNS Number : 7889Z
Genedrive PLC
15 January 2020

genedrive plc
("genedrive" or the "Company")

Notice of Results

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2019 on Tuesday, 4 February 2020.

For further details please contact:

genedrive plc www.genedriveplc.com
David Budd: CEO / Matthew Fowler: CFO +44 (0)161 989 0245

Peel Hunt LLP +44 (0)20 7418 8900
James Steel / Oliver Jackson

Stanford Capital Partners Limited +44 (0)20 3815 8880
Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876 741 001

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB).

Further details can be found at: www.genedriveplc.com and www.genedrive.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORBIMATMTTBBMM